Board of Directors


Sean Carrick

Sean Carrick is the CEO of Nascent Biotech Inc. For over 30 years Mr. Carrick has been in a variety of life sciences companies, including time with Pfizer, Conmed and Maquet Medical, twenty-five of which have been in leadership roles. Mr. Carrick has also been part of several startup ventures including Praecis Pharma and Aveolus. Mr. Carrick was directly involved in a strategic partnership with Hisun Bioray of China. In his time at Nascent Mr. Carrick has led the development of Pritumumab from preclinical to Phase II ready and is currently exploring other therapeutic applications for PTB.

Lowell Holden

Lowell Holden has been the CFO and Chief Accounting Officer of the Company since May 2014.  Since 1983, Mr. Holden has owned and operated his own consulting firm, LS Enterprises, Inc., which provides business consulting, accounting and other services to businesses.  Mr. Holden has a broad range of business experience including managing, securing financing, structuring of transactions, and is experienced and knowledgeable in managing relationships with customers, financing institutions and stockholders. Mr. Holden also has a background in assisting companies in fulfilling their financial auditing and SEC reporting requirements. Mr. Lowell Holden has a Bachelor’s of Science degree from Iowa State University.

Douglas Karas

Effective April 4, 2016, Douglas J. Karas was elected as a Director of Nascent Biotech Inc., to serve until his successor is elected and qualified.

Mr. Karas was previously with Franklin Templeton Investments for 20 years.  Serving in a multitude of positions from the front to back-office.  Positions include,Vice President, Performance Analysis and Investment Risk, Director – Financial Business Processes & Systems, Senior Manager Financial Operations, Manager Financial Program Management Office and Manager Treasury Accounting Control Compliance.

Mr. Karas’ has extensive operations management, consulting, risk and regulatory compliance, re-engineering, project management, and system development experience that cuts across operations and applications.  He has exposure to treasury cash, deal and risk; revenue calculations and recognition; external and internal financial reporting (including 10-K/10-Q, Business Line Profitability, Transfer Pricing and Fund Profitability), financial instruments (dollar rolls, derivatives, ABS and MBS- Security set-up and Maintenance, Pricing, Revenue Recognition, etc.); and Procedures of Portfolio Managers and Investment Advisors in accordance with the Securities Act of 1933 and 1934, Investment Company and Investment Advisor Acts of 1940. Prior to joining Franklin Templeton, Mr. Karas held positions with Transamerica Life Companies and Federated Investors.

Mr. Karas graduated with a B.S. in business, accounting from the University of Pittsburgh and is a Certified Public Accountant.

Delivering human antibodies for the treatment of cancer